Nantkwest (NK) Sees Large Volume Increase

Share on StockTwits

Shares of Nantkwest Inc (NASDAQ:NK) saw unusually-high trading volume on Tuesday . Approximately 863,506 shares traded hands during mid-day trading, an increase of 210% from the previous session’s volume of 278,145 shares.The stock last traded at $1.33 and had previously closed at $1.22.

NK has been the subject of a number of recent research reports. ValuEngine cut shares of Nantkwest from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Citigroup raised shares of Nantkwest from a “sell” rating to a “neutral” rating and reduced their target price for the company from $3.00 to $2.00 in a research report on Friday, November 30th. Finally, Zacks Investment Research raised shares of Nantkwest from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Thursday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $2.33.

The stock has a market cap of $104.40 million, a PE ratio of -1.12 and a beta of 2.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.26 and a current ratio of 3.26.

A number of institutional investors and hedge funds have recently bought and sold shares of NK. Candriam Luxembourg S.C.A. bought a new stake in Nantkwest during the fourth quarter worth about $270,000. Renaissance Technologies LLC lifted its position in Nantkwest by 34.6% during the third quarter. Renaissance Technologies LLC now owns 700,567 shares of the biotechnology company’s stock worth $2,592,000 after purchasing an additional 180,167 shares during the period. D. E. Shaw & Co. Inc. lifted its position in Nantkwest by 338.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 180,595 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 139,431 shares during the period. Bridgeway Capital Management Inc. lifted its position in Nantkwest by 75.0% during the third quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 75,000 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Nantkwest during the fourth quarter worth about $84,000. 10.83% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Nantkwest (NK) Sees Large Volume Increase” was first posted by Highlight Press and is owned by of Highlight Press. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://highlightpress.com/2019/03/22/nantkwest-nk-sees-large-volume-increase.html.

Nantkwest Company Profile (NASDAQ:NK)

NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Recommended Story: Day Trading

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.